bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY

bioAffinity Technologies, Inc.

Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.
CyPath Lung test volume +216% YoY; H1 revenue from test +159% to ~$835k; 1,097 reports vs 390.
Cash and equivalents $2.4M at June 30, 2026 vs $6.4M at Dec 31, 2025; completed $3.2M public offering in June.
Pipeline: asthma/COPD diagnostics and skin cancer therapeutics; longitudinal trial at 11 sites incl. VA.
Physician offices ordering test up 122%; existing clients' orders +71% H1 YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.